Pharmafile Logo
Pharmafocus logo
Advanced Search

Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal

May 19, 2016
Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results

Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …

News
clinical_trial_3

Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016
Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …

News
bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

May 19, 2016
Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …

News

Bayer makes bid for Monsanto

May 19, 2016
Manufacturing and Production, Sales and Marketing Bayer, agrochemical, bid, monsanto, takeover

Bayer (ETR: BAYN) has made a move to consolidate its position in the agrochemical sector with an unsolicited takeover bid …

News
rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016
Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …

News
roche__tree

Roche confirms over 200 job cuts at Irish facility

May 18, 2016
Manufacturing and Production Roche, clare, clarecastle, closure, irish site, job cuts, job losses

Swiss pharmaceutical company Roche (VTX: ROG) has confirmed that 240 jobs are to go at their Irish site in Clare, …

News

AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials

May 18, 2016
Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III

AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …

News
sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016
Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …

News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …

News

Novartis splits pharmaceuticals division into two business units

May 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …

News
opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …

News
michael_becker

Relmada Therapeutics appoints new chief financial officer

May 17, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing chief financial officer, relmada

Michael D. Becker has been appointed the new chief financial officer at Relmada Therapeutics. Becker joined the company in 2014 …

Appointment
biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016
Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …

News
actelion

Actelion granted EU approval for hypertension treatment

May 17, 2016
Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension

Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …

News
allergan

Allergan’s chronic eye disease treatment meets endpoints in pivotal trials

May 17, 2016
Manufacturing and Production, Sales and Marketing Allergan, FDA, chronic eye disease

Allergan has announced positive top line results from two pivotal late-stage trials for the first and only neurostimulation device for …

News
astrazeneca_plaque

AstraZeneca says its respiratory biologic meets primary endpoint in Phase III trial

May 17, 2016
Manufacturing and Production, Research and Development AstraZeneca, asthma drug, benralizumab, drug trial

UK-based AstraZeneca (LSE: AZN) on Tuesday said late stage trials for its biologic asthma drug met the primary endpoint. Chief …

News
dollars_medicines

Valeant announces expanded discounts for Nitropress and Isuprel

May 17, 2016
Manufacturing and Production, Sales and Marketing Isuprel, Nitropress, Valeant, discounts

Valeant Pharmaceuticals (NYSE: VRX) has stepped up its public relations campaign with an announcement of expanded discounts for Nitropress (nitroprusside) …

News
stocks3

Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge

May 17, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …

News
pfizerbrussels

Pfizer to acquire Anacor in $5.2 billion deal

May 16, 2016
Manufacturing and Production, Sales and Marketing 5.2 billion, FDA, Pfizer, acquisition, anacor, crisaborole, merger

Pfizer (NYSE: PFE) has acquired Anacor Pharmaceuticals (NASDAQ: ANAC) in a deal worth around $5.2 billion, or $99.25 per share. …

News
mylan_building

Mylan to buy Renaissance’s dermatology business for up to $1 billion

May 16, 2016
Research and Development, Sales and Marketing Mylan, generics, merger and acquisition

Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026